MOLOGEN AG: Abu Dhabi health authorities do not grant permission for patient treatment

The Berlin-based biotechnology company MOLOGEN AG announced today that its partner NMC Group has been informed by the local health authorities (GAHS) responsible for Abu Dhabi, not to grant permission for patient treatment by MOLOGEN´s cell-based gene therapy for regulatory reasons.

MOLOGEN will review alternative solutions in the other Emirates in short term. In March 2006, MOLOGEN had entered an exclusive agreement with NMC Group for the distribution of the cell-based gene therapy in the hospitals owned by NMC.

About MOLOGEN

MOLOGEN AG is a listed biopharmaceutical company with headquarters in Berlin (Frankfurt Stock Exchange, Regulated Market, ISIN DE0006637200). On the basis of patented technologies (MIDGE and dSLIM), MOLOGEN develops DNA-based vaccines and therapeutic agents for the prevention and treatment of a wide range of serious illnesses.

Disclaimer concerning prognoses

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.

back to the overview